AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

1. ANAB's rosnilimab showed JAK-like efficacy in rheumatoid arthritis Phase 2b trial. 2. Efficacy included significant improvements in disease activity and remission rates. 3. HC Wainwright upgraded ANAB from Neutral to Buy with a new price target. 4. Upcoming ulcerative colitis data expected in Q4 2025 may influence stock. 5. Current stock down 12.1% at $20.66 despite positive trial data.